¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¹ÙÀÌ·¯½º°£¿° Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2023-12-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

¹ÙÀÌ·¯½º°£¿° Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2023-12-16
±³À°ÀÏÀÚ : 2023-12-16
±³À°Àå¼Ò : °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°­´ç

±³À°ÁÖÁ¦ : ¹ÙÀÌ·¯½º°£¿° Ä¡·áÀÇ ÃÖ½ÅÁö°ß

ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¹ÙÀÌ·¯½º°£¿° ¿¬±¸È¸

´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-707-0091

À̸ÞÀÏ : kasl@kams.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°­´ç 13:35~14:00 Clinical Insights into Novel Viral Markers for Outcome Prediction in CHB ±èÅÂÇü(ÇѸ²´ë)

±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°­´ç 14:00~14:25 Novel strategies for anti-HBV nucleos(t)ide analogues treatment ÃÖ¿ø¹¬(¿ï»ê´ë)

±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°­´ç 14:25~14:50 Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals ÀåÀº¼±(¼­¿ï´ë)

±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°­´ç 14:50~15:15 Experimental studies targeting for functional and sterlizing cure for CHB ±è±Õȯ(¼º±Õ°ü´ë)

±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°­´ç 15:50~16:10 Hepatitis B : update based on the current therapy ÀÌÀç½Â(¿¬¼¼´ë)

±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°­´ç 16:10~16:30 Hepatitis B : novel therapeutic agents ±èÈñ¾ð(°¡Å縯´ë)

±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°­´ç 16:30~16:50 Hepatitis C, D, others and coinfection °­¿ø¼®(¼º±Õ°ü´ë)

±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°­´ç 16:50~17:00 An artificial intelligence model for prediction of hepatocellular carcinoma development after oral antiviral therapy in patients with chronic hepatitis C ÀÌÀ¯¸²(°æºÏ´ë)

±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°­´ç 17:00~17:10 Influence of viral load and fibrotic burden on hepatocellular carcinoma risk at phase change to immune-active phase in chronic hepatitis B ÀüÈ£¼ö(ÀÌÈ­¿©´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¹ÙÀÌ·¯½º°£¿° Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2023-12-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³âµµ Á¦3ȸ ´ëÇѽŰæ°úÇÐȸ ½Å°æ°èÁúȯ ½º¸¶Æ®ÇコÄÉ¾î ½ÉÆ÷Áö¾ö : 2023-12-16
´ÙÀ½±Û 2023 ´ëÇÑôÃß¿Ü°úÇÐȸ ¿äÃß¿¬±¸ÇÐȸ ½ÉÆ÷Áö¿ò : 2023-12-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 34 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 34 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 30 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 26 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 30 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 41 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 17 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 23 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 22 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 22 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 21 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 19 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 22 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 25 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 26 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷